Deciphering the Turnover of Proteome and Phosphoproteome in Alzheimer's Disease - Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by memory decline and hallmark neuropathologies, including amyloid plaques and tau tangles. Emerging evidence suggests that disrupted proteostasis—particularly impaired protein degradation systems—plays a critical role in AD pathogenesis. Because neurons are long-lived and possess limited regenerative capacity, they are especially susceptible to the accumulation of misfolded or aberrantly modified proteins. However, at a systems level, the dynamics of protein and phosphoprotein turnover in AD remain poorly understood. We hypothesize that altered regulation of proteome and phosphoproteome turnover in specific brain regions and cell types drives AD onset and progression. We further propose that site-specific post-translational modifications, especially phosphorylation, directly modulate protein stability and degradation, and that dysregulation of these processes exacerbates pathological protein accumulation and neuronal dysfunction. To test these hypotheses, we will employ stable isotope labeling, quantitative multiplexed mass spectrometry (MS), and phosphopeptide enrichment to systematically profile protein turnover rates, phosphoproteome dynamics, and protein aggregation in genetically distinct AD mouse models at pre-symptomatic and symptomatic stages. These datasets will also be cross-referenced with human AD proteomic data to validate key findings and identify functional dependencies on protein degradation pathways and processes in AD. Additionally, we will perform spatially resolved turnover mapping using laser capture microdissection (LCM) and high-resolution MALDI imaging MS, enabling us to reveal protein turnover regulation with regional, cell-type, and single-cell-level precision. Furthermore, we will use phosphorylation-targeting technologies such as PhosTACs, kinase inhibitors, and phospho-mutant constructs to functionally assess phosphosites prioritized by turnover profiling and their roles in regulating protein stability in vitro, in primary neurons, and in human iPSC-derived neural cell models. Together, our studies provide a comprehensive discovery into proteostasis alterations in AD, uncovering critical regulatory mechanisms and revealing how protein degradation systems fail during neurodegeneration. By integrating proteomics, phosphoproteomics, protein turnover analysis, and spatial biology, this work will facilitate new therapeutic approaches targeting proteostasis networks to treat or prevent AD.